Don't miss a thing by getting the latest from the Manchester Evening News sent direct to your inbox People under the age of 30 will be offered an alternative to the Oxford/AstraZeneca jab.
The UK's vaccine advisory body has said the decision is due to mounting evidence of the vaccine's link to rare blood clots. But the huge benefits of the Oxford/AstraZeneca vaccine continue to outweigh any risks for most people in preventing Covid-19 and serious disease, the Medicines and Healthcare products Regulatory Agency (MHRA) added.
A review by the European Medicines Agency’s safety committee concluded on Wednesday that “unusual blood clots with low blood platelets should be listed as very rare side effects” of the Oxford/AstraZeneca vaccine.
Read more on manchestereveningnews.co.uk